Reishi (Ganoderma) has significant therapeutic value in patients with FSGS. - GreenMedInfo Summary

Abstract Title:

Ganoderma lucidum suppresses endothelial cell cytotoxicity and proteinuria in persistent proteinuric focal segmental glomerulosclerosis (FSGS) nephrosis.

Abstract Source:

Clin Hemorheol Microcirc. 2004;31(4):267-72. PMID: 15567896

Abstract Author(s):

Narisa Futrakul, Tasanee Panichakul, Punnee Butthep, Prasit Futrakul, Pim Jetanalin, Suthiluk Patumraj, Prasong Siriviriyakul

Abstract:

A persistent proteinuria is commonly observed in nephrotic patient with focal segmental glomerulosclerosis (FSGS) under treatment with prednisolone+/-cyclophosphamide or with vasodilators (ACEI+AII receptor antagonist, calcium channel blocker and antiplatelet agent). Fourteen such patients with persistent proteinuria were subject to be treated with Ganoderma lucidum. Initial study revealed an enhanced endothelial cell cytotoxicity induced by patient's serum, and an altered immunocirculatory balance with predominant proinflammatory cytokine TNF alpha activity in the presence of defective anti-inflammatory cytokine interleukin-10. Treatment with Ganoderma lucidum suppressed endothelial cell cytotoxicity, restored immunocirculatory balance and successfully suppressed proteinuria in all of these 14 patients.

Article Published Date : Jan 01, 2004

Study Type : Human Study

Additional Links

Substances : Reishi Mushroom : CK(406) : AC(202)

Diseases : Focal segmental glomerulosclerosis (FSGS) : CK(10) : AC(1)

Print Options

Some features are currently member only features. If you are already a member, please login. Otherwise, click here to become a member.

Printer-friendly version

Reishi (Ganoderma) has significant therapeutic value in patients with FSGS. - GreenMedInfo Summary

Print Options

Key Research Topics

Subscribe to our informative Newsletter & receive The Dark Side of Wheat Ebook

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.